I'm LongbridgeAI, I can summarize articles.CollPlant Biotechnologies (CLGN.US) climbed nearly 9% during regular trading to $4.439.
The stock is up 13.84% over the past five sessions and down 68.29% year to date. It sits 68.34% above its 52-week low of US$2.637. The intraday swing reached 11.03%.
The Nasdaq Composite is down 4.10% over the past five sessions and up 9.25% year to date.
The company's subsidiary LightSolver signed a multi-year contract with the Israeli Ministry of Defense to develop and deliver laser processing units. The agreement includes an initial order covering the first 12 months of photonic computing collaboration, following the successful completion of proof-of-concept work with the ministry's Research and Development Authority.
Separately, CollPlant appointed Deputy CEO and CFO Eran Rotem as chief executive officer, succeeding Yehiel Tal, effective Nov. 2, 2026. Tal also stepped down as interim chairman of the board on the same date. The leadership transition is part of a broader cost-reduction strategy that includes halting research and development in regenerative medicine.
Based on public media reports. AI-generated; not investment advice.